AstraZeneca

AstraZeneca reported a 45% increase in net profit and a 9% rise in revenue for 2025, driven by strong cancer drug sales. The company is expanding its presence in the United States and China, aiming for $80 billion in annual revenue by 2030. Its shares rose in London trading following the positive earnings report.

AstraZeneca announced a significant investment of $15 billion in China through 2030 to expand its medicines manufacturing and research and development. This move highlights the company's commitment to the Chinese market and is expected to boost its presence and innovation capabilities in the region.

AstraZeneca is collaborating with AIM ImmunoTech Inc. and Erasmus MC on the DURIPANC study, contributing its anti-PD-L1 immune checkpoint inhibitor AstraZeneca===Durvalumab. The collaboration highlights AstraZeneca's involvement in advanced cancer research.

AstraZeneca, as the developer of the Oxford–AstraZeneca COVID-19 vaccine, is directly impacted by the findings, which offer a pathway to improve the safety of its adenovirus-based vaccine technology.

AstraZeneca, a multinational innovator, may see improved patient access to its therapies in India following the customs duty exemption on cancer drugs.